When trying to solve the enigmatic power of arsenic in inducing an APL cure, researchers discovered that the drug targeted PML/RARA, initiating its destructive proteolysis, which revealed PML as the first target of the RNF4 enzyme [52,53,152]. This evidence concerns the gene RNF4 and acute promyelocytic leukemia.